Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Constellation Pharmaceuticals, Inc.

Latest From Constellation Pharmaceuticals, Inc.

MorphoSys May Be One To Watch at J.P. Morgan

Excitement continues to grow around pelabresib after the presentation of promising data for the German group’s myelofibrosis drug.

Financing Cancer

MorphoSys Keeps The Faith Despite Mixed Data For Myelofibrosis Combo

The jury is out on whether regulators have seen enough to approve pelabresib.

Cancer Clinical Trials

MorphoSys Confident Of A Win Over AbbVie In Myelofibrosis

Sales of the lymphoma drug Monjuvi continue to underwhelm but MorphoSys believes that its investigational BET inhibitor, pelabresib, can become a standard of care for the rare bone marrow disease myelofibrosis.

Sales & Earnings Business Strategies

Asia Deal Watch: Astellas Expands Protein Degrader R&D Capability With PeptiDream Collaboration

Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics